Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
OwnerMark THROSBY, Cecilia Anna Wihelmina GEUIJEN +2inventors
InventorsMark THROSBY, Cecilia Anna Wihelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.
Claims21
A method of treating an individual that has an ErbB-2 and ErbB-3 positive cell, which cell comprises an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location, the method comprising administering to the individual a bispecific antibody that comprises a first antigen-binding site that can bind an extracellular part of ErbB-2 and a second antigen-binding site that can bind an extracellular part of ErbB-3.
A method of treating an individual that has an ErbB-2 and ErbB-3 positive tumor, wherein cells of the tumor express an NRG1 fusion gene comprising at least the 3′ end of the NRG1-gene fused to a 5′ sequence from a different chromosomal location, the method comprising administering to the individual a bispecific antibody that comprises a first antigen-binding site that can bind an extracellular part of ErbB-2 and a second antigen-binding site that can bind an extracellular part of ErbB-3.
Dependencies are inferred from the claim text.